PT2385

· Peloton Therapeutics, a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for PT2385, covering 2015-12-10 to 2024-06-17. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) [Phase 1]

See pricing